While abundant data exist documenting variables associated with early platelet engraftment after autologous PBPC transplantation, data concerning later sustained platelet engraftment is sparse. We retrospectively examined a series of 80 patients undergoing autologous PBPC transplantation with respect to their platelet count 6 weeks after transplant. Underlying diagnoses included breast cancer (n = 33), non-Hodgkin's lymphoma (n = 32), Hodgkin's disease (n = 9), and other hematologic malignancies (n = 6). Patients received G-CSF for PBPC mobilization and collected a target threshold number of 2.0 × 10 6 CD34 + cells per kilogram. A univariate analysis revealed that a diagnosis of breast cancer, fewer courses of prior chemotherapy, younger age and complete remission were associated with a higher 6-week platelet count. Additionally, the ability to collect the threshold number of CD34 + with fewer sessions of leukapheresis was also associated with a higher 6-week platelet count. The platelet count and the white blood cell count at the initiation of PBPC collection was also associated with a higher 6-week platelet count. A multivariate analysis revealed a higher platelet count on the first day of pheresis, fewer phereses required to collect 2 × 10 6 CD34 + cells per kilogram, and a diagnosis of breast cancer were all associated with a higher 6-week posttransplant platelet count. Seven patients failed to reach a 6-week platelet count of 30 × 10 9 /l and an additional five patients had a platelet count of 30-50 × 10 9 /l. We conclude that underlying clinical characteristics, as well as hematologic variables at the time of PBPC collection, influence later, sustained platelet engraftment. A percentage of patients have poor sustained platelet engraftment and may be candidates for new cytokines that specifically target megakaryocyte growth and development.
10-18 days after infusion of autologous PBPCs. Several studies have described a correlation of the total number CD34 + cells infused with early platelet engraftment. However, the literature documenting late, sustained platelet engraftment is sparse. One small series described a relationship between total CD34
+ cells infused with later (6 months post transplant) platelet engraftment. 1 The importance of sustained platelet engraftment is significant. Radiation therapy, often administered after transplant, may be delayed for thrombocytopenia. 2, 3 Additionally, a minority of patients are platelet transfusiondependent for an extended period of time. To define the issue of sustained platelet engraftment further, we retrospectively reviewed a series of 80 patients undergoing autologous PBPC transplantation. We routinely evaluate patients in our outpatient clinic 6 weeks from their date of PBPC infusion and we used the 6-week post-transplant platelet count as a reference point. In addition to conventional clinical variables that may be associated with engraftment, such as underlying diagnosis and patient age, we also examined clinical variables that might have an impact on platelet engraftment. We have previously described a correlation with the pretransplant platelet count and platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation, 4 and we have recently reported that patients experiencing a robust G-CSF-induced leukocytosis during PBPC mobilization have excellent CD34
+ yields during PBPC collection. 5 Thus, we elected to examine several clinical variables at the time of collection of PBPCs as additional possible variables associated with sustained platelet engraftment.
Materials and methods

Patient characteristics
We retrospectively studied 80 adult patients primed with G-CSF undergoing high-dose chemotherapy with autologous PBPC transplantation at the Cleveland Clinic Foundation from January to December 1996. The patient characteristics are shown in Table 1 .
PBPC collection and processing
All patients received cytokine priming for PBPC collection. G-CSF (filgrastim) 5-10 g per kilogram per day was administered subcutaneously for 8 to 10 days with PBPC 548 Months from diagnosis to transplant 24 (range, 3-212) (median) CR = complete remission; PR = partial remission; NR = no response. collection beginning on day +5. The total yield of PBPC collection was at least 2 × 10 6 CD34 + cells per kilogram. The patients were harvested on COBE Spectra leukopheresis machine (COBE, Denver, CO, USA).
CD34
+ analysis
Peripheral blood progenitor cells obtained by apheresis were collected into ACD-A anti-coagulant. An aliquot of each collection was counted and a minimum 20 × 10 6 cells were submitted for flow cytometric evaluation. For each sample, 250 000 events were required as list mode data using a Cell Quest (BDIS, San Jose, CA, USA) software document which had been specifically tailored and stored for this purpose. Total CD34 + positive cells were calculated by multiplying the percentage of CD34 + cells in the flow cytometric analysis by the total number of nucleated cells in the apheresis product. This number was divided by the patient's actual weight to give the total CD34 + cells/kg.
Transplant protocol
The patients were treated with one of four chemotherapy (only) preparative regimens. ). G-CSF was routinely given at a dose of 5 g/kg per day beginning 1 to 5 days after the infusion of PBPC. G-CSF was discontinued after patients reached 1.0 × 10 9 neutrophils per mm 3 on 2 consecutive days.
Supportive care
Patients received prophylactic antibiotics consisting of oral acylovir and ciprofloxacin. Low-dose amphotericin (0.2 mg/kg) was begun the day after PBPC infusion. Patients who experienced persistent fevers had their antibiotic coverage broadened. Patients received red blood cell transfusions to maintain a hemoglobin of greater than 9 g/dl, and platelet transfusions were given for a platelet count of less than 10 × 10 9 /l.
Definitions
A normal platelet count is defined as greater than or equal to 150 × 10 9 /l. 'Day 1' refers to values obtained on the first day of leukapheresis to collect PBPCs (the 5th day of G-CSF priming).
Statistical analysis
Data is presented as percentage or medians as appropriate. Correlations were done using the Spearman correlation procedure. Associations between groups were tested using a 2 test. Differences in values between groups were tested using a Wilcoxon rank sum test. A stepwise multivariable regression was used to determine which factors are independently associated with the 6-week platelet level after adjusting for other factors. A P value р0.05 was considered statistically significant with P values 0.05 Ͻ P Ͻ 0.10 being marginally significant.
Results
The median platelet count 6 weeks after autologous PBPC transplant was 111 × 10 9 /l (range, 4-277). The pretransplant characteristics associated with the 6-week platelet count are shown in Table 2 . A univariate analysis revealed that a diagnosis of breast cancer, fewer courses of prior chemotherapy, complete remission and younger age (P = Variables associated with 6-week post-PBPCT platelet count B Bolwell et al 549 Table 2 Patient characteristics associated with the 6-week post-transplant platelet count 0.009) were associated with a higher 6-week platelet count.
Of the 41 patients with non-Hodgkin's lymphoma or Hodgkin's disease, 20 (49%) had bone marrow involvement of lymphoma. The mean 6 week platelet count was 103 × 10 9 /l for those without marrow involvement, and 93 × 10 9 /l for those with marrow involvement (P = 0.44).
The median total yield of CD34 + cells was 2.74 × 10 /l (range, 6-69). There was a strong correlation of the 6-week platelet count with the total number of CD34
+ cells infused (Figure 1) . A higher day 1 platelet count and WBC correlated with a higher 6-week post-transplant platelet count, as shown in Table 3 .
We next performed a multivariate analysis of variables associated with the 6-week platelet count. Variables tested included patient age, underlying diagnosis, prior exposure to radiation therapy, disease status, courses of prior chemotherapy, day 1 white blood count, day 1 platelet count, dose of G-CSF for PBPC mobilization, number of phereses required to collect 2 × 10 6 CD34 + cells, gender, and total number of CD34 + cells infused. The multivariate analysis found four factors associated with a higher 6-week platelet level: a diagnosis of breast cancer (P = 0.001), younger age (P = 0.03), fewer phereses required to collect a threshold target of CD34 + positive cells (P = 0.003), and higher day 1 platelet count (P = 0.001). Further analysis showed that age was only an important factor in the breast cancer group. Because of this interaction between age and diagnosis, the multivariate analysis was Table 3 Correlation of clinical variables at the start of pheresis for PBPC collection with the 6-week post-transplant platelet count performed separately by diagnosis. The number of phereses required to collect 2 × 10 6 CD34 + cells per kilogram, and a higher day 1 platelet count, were significant variables in both groups as shown in Table 4 . Interestingly, the multivariate analysis revealed the total number of CD34 + cells infused was not a significant variable with respect to the 6-week platelet count, although a univariate analysis did determine that those patients receiving at least 5 × 10 6
CD34
+ cells/kg had a higher 6 week platelet count than did those receiving 2-5 × 10 6 CD34 + cells/kg (platelet count 144 vs 100 × 10 9 /l, P = 0.006). Being somewhat surprised that the total number of CD34 + cells collected did not correlate with the 6-week platelet engraftment, we then examined our early, initial engraftment to a platelet value of 20 × 10 9 /l. A multivariate analysis found three variables associated with early platelet engraftment: the total number of CD34 + cells infused (P = 0.005); the day 1 platelet count (P = 0.02); and a diagnosis of breast cancer (P = 0.0005). Patients with breast cancer experienced early initial platelet engraftment in a mean of 13 days after PBPC infusion compared with a mean of 25 days for other diagnoses.
Twelve patients (15%) failed to achieve a 6-week platelet count of 50 × 10 9 /l. Seven of 80 patients (9%) had a 6-week platelet count of less than 30 × 10 9 /l. Five of these seven patients had non-Hodgkin's lymphoma, and two had breast cancer. The patients with a platelet count less than 30 × 10 9 /l had a lower day 1 platelet count (124 vs 216 × 10 9 /l, P = 0.002) and a marginally lower CD34 + yield (2.19 vs 2.77 × 10 6 /kg, P = 0.09) than did the other 73 patients.
Discussion
Platelet engraftment after autologous PBPC transplantation is generally reported as the time required to reach a sustained platelet count of either 20 or 50 × 10 9 /l. This study examined platelet engraftment from a slightly different perspective, in that we selected a time frame at which we routinely evaluate patients post-transplant (6 weeks posttransplant) and looked at variables affecting the platelet count at that particular time-point. We found that two patient characteristics (underlying diagnosis and age), as well as two clinical characteristics of progenitor cell collection (the platelet count on the first day of pheresis, and the number of phereses required to collect a threshold number of CD34 + cells) correlated with the 6-week post-transplant platelet count. To the best of our knowledge, the diagnosis of breast cancer (as compared to lymphoid malignancies) has not been previously reported to be associated with improved long-term platelet engraftment. Reiffers et al 6 conducted a study of long-term engraftment in patients undergoing PBPC transplant for hematologic malignancies, and found that patients transplanted for non-Hodgkin's lymphoma experienced more rapid platelet engraftment than did those transplanted for multiple myeloma or AML. They also found that platelet engraftment was more rapid if there was a shorter interval from diagnosis to transplant. The time from diagnosis to transplant was actually longer for our breast cancer patients than our other diagnoses (33 months vs 19 months, P = 0.29). The percentage of patients who received prior radiation therapy was higher in the breast cancer population (55% vs 36%, P = 0.10). The mechanism of enhanced sustained platelet engraftment in breast cancer patients is unclear. Several possibilities exist, including differences in bone marrow microenvironment, as well as the possibility of immunologic abnormalities in lymphoma patients resulting in thrombocytopenia after transplantation. While difficult to quantify, we believe that the difference may reflect the fact that a certain percentage of lymphoma patients is heavily pretreated, and may have active disease at the time of transplant, which may adversely affect sustained platelet engraftment.
Many authors have shown that the time to platelet engraftment to 20 or 50 × 10 9 /l correlates with the number of progenitor cells infused as measured by either CD34 + cells, or CFU-GMs infused. [7] [8] [9] [10] Our analysis showed that the total number CD34 + cells was highly predictive of the 6-week platelet count in the univariate analysis, but was not a statistically significant variable on the multivariate analysis. We then examined the relationship of CD34 + cells to early platelet engraftment, as measured by the time to achieve a platelet count of 20 × 10 9 /l and found that the number of CD34 + cells did, in fact, correlate with early platelet engraftment in a multivariate analysis. Our analysis showed that platelet count on the first day of phereses correlated with the 6-week platelet count. We believe the likely explanation for these results is that the yield of CD34 + cells, and the day 1 platelet count, are related variables. They are likely both a measure of marrow 'health', or the ability to produce hearty progenitor cells. From a clinical perspective, the utility of the day 1 platelet count may be that thrombocytopenic patients are likely to have problematic later platelet engraftment. Such thrombocytopenic patients may be candidates for novel cytokine mobilization strategies, which may include stem cell factor, FLT-3 ligand, or other broad-acting cytokines. [11] [12] [13] Alternatively, these patients at high risk for poor sustained platelet engraftment may be candidates for clinical trials utilizing megakaryocyte stimulating cytokines after PBPC transplantation. 14 A small percentage of patients experienced significant problems with sustained platelet engraftment after PBPC platelet transplantation. Many series have reported that some patients require 100 or more days to reach a platelet count of 20 to 50 × 10 9 /l. Haas et al 15 noted delayed platelet recovery of 1 to 6 years seen in 12 of 145 patients in his large series examining engraftment after autologous PBPC transplantation. Bentley et al 16 noted that seven of 51 patients were platelet or red blood cell transfusion dependent for greater than 100 days after autologous PBPC transplantation. Reiffers et al 6 noted that 34% of a series of 118 patients undergoing autologous PBPC transplantation with hematologic malignancies had not reached a platelet count of 50 × 10 9 /l by 60 days post-transplant. Other series have also documented that a minority of patients has poor sustained platelet engraftment. [17] [18] [19] We found that seven of 80 patients (9%) undergoing autologous PBPC transplantation had not reached a platelet count of 30 × 10 9 /l at the 6-week post-transplant time-frame. Five of these patients had nonHodgkin's lymphoma, and two had breast cancer. This is a significant clinical problem affecting many patients as the number of PBPC transplants continue to increase. As discussed earlier, new broadly acting cytokines might enhance PBPC yields for patients at risk for poor later engraftment. Similarly, cytokines specifically aimed at megakaryocyte growth, such as thrombopoietin, 14, [19] [20] [21] [22] may be of significant clinical utility in these 'outlier' patients with serious problems with sustained platelet engraftment. The utility of platelet stimulating agents such as thrombopoietin in this clinical setting remains to be studied.
Our threshold value for the number of PBPCs collected was 2.0 × 10 6 CD34 + cells/kg. Siena et al 23 has described a series of patients in whom a minimum of 8 × 10 6 CD34 + cells/kg were collected for autologous PBPC transplantation, and found that their patients experienced durable normal hematopoiesis. We found that patients who received у5 × 10 6 CD34 + cells/kg had a higher 6-week platelet count than those who received 2-5 × 10 6 CD34 + cells/kg (mean platelet count 144 × 10 9 /l vs 100 × 10 9 /l). It is possible that a threshold of 2 × 10 6 CD34 + cells/kg is adequate for early engraftment, but may be less than optimal, at least in some patients, for later engraftment.
In conclusion, we have shown that clinical and hematoogical factors at the time of PBPC collection may reflect the ability of the patients to experience adequate sustained platelet engraftment. Additionally, the 6-week post-transplant platelet count may be affected by the underlying diagnosis of the patient. These variables may be of importance in the design of future clinical trials utilizing novel cytokines for PBPC mobilization, as well as for enhancing platelet engraftment after PBPC transplantation.
